Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) (Cardiovascular) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease Peripheral Vascular Disease – Drugs In Development, 2021, provides an overview of the Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline landscape.Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease Peripheral Vascular Disease – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 10, 3, 15, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.s

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular).

– The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Alucent Biomedical Inc

AnGes Inc

AptaBio Therapeutics Inc

ARCA biopharma Inc

ArtGen Inc

Athera Biotechnologies AB

Athersys Inc

Bayer AG

Betagenon AB

BiogenCell Ltd

Celularity Inc

Chengdu Shibeikang Biomedical Technology Co Ltd

Constant Therapeutics LLC

CuRAGE Therapeutics Inc

Exodos Life Sciences Limited Partnership

Foresee Pharmaceuticals Co Ltd

Gurus BioPharm

Helixmith Co Ltd

Hemostemix Inc

ID Pharma Co Ltd

IPCA Laboratories Ltd

JanOne Inc

Juventas Therapeutics Inc

Laboratoris Sanifit SL

LipimetiX Development Inc

LTT Bio-Pharma Co Ltd

MediaPharma SRL

Nangiotx Inc

Novo Nordisk AS

Pharmosa Biopharm Inc

Polysan NTFF Ltd

Recardio GmbH

Resverlogix Corp

Reven Pharmaceuticals Inc

Sorrento Therapeutics Inc

Stemedica Cell Technologies Inc

Symic Bio Inc

Vascugen Inc

Venturis Therapeutics Inc

VESSL Therapeutics Ltd

Zelira Therapeutics Ltd

Zhittya Genesis Medicine Inc

Table of Contents

Table of Contents

Introduction

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Overview

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Therapeutics Development

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Therapeutics Assessment

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Companies Involved in Therapeutics Development

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Drug Profiles

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Dormant Projects

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Discontinued Products

Peripheral Arterial Disease (PAD)/ Peripheral Vascular - Product Development Milestonesh

Appendix

List of Tables

List of Tables

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Alucent Biomedical Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AnGes Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by AptaBio Therapeutics Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ARCA biopharma Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ArtGen Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athera Biotechnologies AB, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Athersys Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Bayer AG, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Betagenon AB, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by BiogenCell Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Celularity Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Chengdu Shibeikang Biomedical Technology Co Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Constant Therapeutics LLC, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by CuRAGE Therapeutics Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Exodos Life Sciences Limited Partnership, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Foresee Pharmaceuticals Co Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Gurus BioPharm, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Helixmith Co Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Hemostemix Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by ID Pharma Co Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by IPCA Laboratories Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by JanOne Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Juventas Therapeutics Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Laboratoris Sanifit SL, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by LipimetiX Development Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by LTT Bio-Pharma Co Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by MediaPharma SRL, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Nangiotx Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Novo Nordisk AS, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Pharmosa Biopharm Inc, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Pipeline by Polysan NTFF Ltd, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Dormant Projects, 2021

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports